Niger

Sanofi-aventis & EPIVAC

EPIVAC (from EPIdemiology & VACcinology) is a comprehensive, one-year, on-the-job professional training program in epidemiology, applied computing, vaccinology and management of health programs for public health officers in West Africa, culminating in an inter-university diploma in 'Organization and Management of Public Immunization Programs in Developing Countries' awarded by the universities of Cocody-Abidjan (Ivory Coast) and Paris-Dauphine (France). The program is a Sanofi Pasteur, the vaccines division of sanofi-aventis, contribution to the GAVI Alliance.

PMTCT: Abbott Rapid HIV Test Donation Program

Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.

Novo Nordisk: Differential Pricing on Insulin

Among the targets for UN Millennium Development Goal 8 is a call for partnerships with pharmaceutical companies to provide access to affordable essential drugs in developing countries. Since 2001, Novo Nordisk has offered human insulin to the public health systems in Least Developed Countries (LDCs) at prices which do not to exceed 20% of the average price in Europe, Japan and North America. In 2009, Novo Nordisk offered this pricing scheme to all 49 LDCs, of which 36 used it to buy insulin at or below this price, compared to 32 in 2008.

Novartis Coartem

Coartem is the first World Health Organization-prequalified fixed-dose, artemisinin-based combination therapy (ACT) antimalarial, approved by stringent regulatory authorities and on the WHO Model List of Essential Medicines. Coartem is fast-acting and cures over 97% of patients after a 3-day treatment course. Coartem combines artemether, a derivative of artemisinin (from the Chinese medicinal plant Artemisia annua), with a synthetic substance, lumefantrine, which has not been used as a monotherapy.

Merck Mectizan Donation Program

Onchocerciasis, or river blindness, is a leading cause of infectious blindness in the developing world. The Merck Mectizan Donation Program (MDP) was launched in 1987, when Merck & Co., Inc. announced that it would donate Mectizan (ivermectin), for the treatment of onchocerciasis to all who needed it for as long as needed.

International Trachoma Initiative (ITI)

The International Trachoma Initiative (ITI) is the only organization dedicated solely to the elimination of blinding trachoma.

Global Pharma Health Fund

The Global Pharma Health Fund e.V. (GPHF) is a charitable organization initiated and funded exclusively by donations from Merck KGaA, Darmstadt Germany. In 2007, it took over the work of the former German Pharma Health Fund, which was set up in 1985. The organization aims to improve health care in the context of development assistance, in particular the use of the GPHF-Minilab in the fight against counterfeit drugs.

Global Alliance to Eliminate Lymphatic Filariasis (GAELF)

The Global Alliance to Eliminate Lymphatic Filariasis (GAELF) was created to eliminate one of the world's leading causes of disability and disfigurement as a public health problem by the year 2020. An estimated 120 million people in at least 80 countries of the world suffer from the disease, and one billion (20% of the world's population) are at risk of infection.

Bristol-Myers Squibb's Secure The Future

Secure The Future is a comprehensive initiative to fight HIV/AIDS in sub-Saharan Africa, sponsored by Bristol-Myers Squibb and the Bristol-Myers Squibb Foundation. It combines medical treatment and care, access to antiretroviral medicines, with research, social support with community education, and training for health care professionals with new facilities and infrastructure investments in remote areas of sub-Saharan Africa where resources are extremely limited.

Boehringer Ingelheim Access

Boehringer Ingelheim offers its product Viramune® for single-dose use in the prevention of mother-to-child transmission for free and/or reduced prices.

Pages